行情

GNFT

GNFT

GENFIT S.A.
NASDAQ

实时行情|Nasdaq Last Sale

14.55
+0.55
+3.93%
盘后: 14.55 0 0.00% 16:00 10/14 EDT
开盘
14.80
昨收
14.00
最高
14.80
最低
14.30
成交量
2.41万
成交额
--
52周最高
26.25
52周最低
13.21
市值
5.26亿
市盈率(TTM)
-4.2771
分时
5日
1月
3月
1年
5年

GNFT 新闻

  • 数据:伦交所环球板交易工具(CDI)
  • 新浪财经.1小时前
  • 优步在最新一轮裁员中解雇了350名员工
  • 新浪美股.1小时前
  • 贝佐斯:开会禁止PPT演示是亚马逊最明智的决定
  • 新浪财经.1小时前
  • 苹果否认向腾讯泄露隐私数据 但怀疑者们仍有问题
  • 36氪.1小时前

更多

所属板块

生物技术和医学研究
+0.42%
制药与医学研究
+0.09%

热门股票

名称
价格
涨跌幅

GNFT 简况

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
展开

Webull提供Genfit SA的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。